Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 1517.8%.

  • Pharma's EBIT Margin fell 10906200.0% to 1517.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 731.83%, marking a year-over-year increase of 563400.0%. This contributed to the annual value of 585.84% for FY2025, which is 1426400.0% up from last year.
  • According to the latest figures from Q3 2025, Pharma's EBIT Margin is 1517.8%, which was down 10906200.0% from 580.79% recorded in Q2 2025.
  • Pharma's EBIT Margin's 5-year high stood at 385.41% during Q2 2023, with a 5-year trough of 7764.29% in Q3 2021.
  • Moreover, its 5-year median value for EBIT Margin was 1231.68% (2022), whereas its average is 1829.06%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -64234900bps in 2021, then soared by 65326000bps in 2022.
  • Pharma's EBIT Margin (Quarter) stood at 1679.58% in 2021, then surged by 59bps to 686.14% in 2022, then crashed by -114bps to 1469.61% in 2023, then soared by 50bps to 730.74% in 2024, then crashed by -108bps to 1517.8% in 2025.
  • Its EBIT Margin was 1517.8% in Q3 2025, compared to 580.79% in Q2 2025 and 427.88% in Q1 2025.